Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotechnology company Ligand Pharmaceuticals sank 10% this morning after its quarterly results disappointed Wall Street.
So what: The stock has skyrocketed over the past year on solid royalties and milestone payments, but today's Q2 results are prompting investors to rein in a bit of their excitement. While revenue surged 67% over the year-ago period, a few analysts suggest that there's still too much uncertainty surrounding Ligand's pipeline -- particularly Promacta -- to justify such a seemingly lofty valuation.
Now what: Management now sees full-year EPS of $0.47-$0.50 on revenue of $43 million-$46 million.
"[T]he coming quarters look promising as we anticipate further growth in royalty revenue, potential approvals for a new royalty-bearing drug and label expansions, NDA filings for partnered products and completing our first full year of operational profitability," said CEO John Higgins.
So while Ligand is still way too speculative for average Fools, today's pullback might be an overreaction that biotech-savvy traders may want to pounce on.
The best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why Ligand Pharmaceuticals Shares Plunged originally appeared on Fool.com.Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.